Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
371 Results Found
Putting 340B Program Growth in Context
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.
AHA Report: The 340B Drug Pricing Program
The 340B Drug Pricing Program allows hospitals caring for large numbers of underserved patients to stretch scarce federal resources and provide more comprehensive care by requiring drug companies to offer discounted prices on certain outpatient drugs.
The CY 2026 Outpatient PPS/ASC Payment System Final Rule Webinar
This webinar reviews key provisions proposed in the Outpatient, Ambula
Amicus Briefs
The AHA weighs in on a number of issues of importance to hospitals and health systems, as well as the patients they care for, as they come before the court. Below are our most recent friend-of-the-court briefs.
The Future of 340B: What Hospitals and Rural Communities Need to Know
In this Leadership Dialogue conversation, Tina Freese Decker, president and CEO of Corewell Health and 2025 AHA board chair, joins Aimee Kuhlman, vice president of advocacy grassroots and government relations at the AHA, and Paulette Davidson, president and CEO of Monument Health, to unpack what’s at stake.
AHA, others file suit to block unlawful 340B changes threatening patient care
The AHA, the Maine Hospital Association and four safety-net health systems from across the country Dec. 1 filed a lawsuit in the U.S. District Court for the District of Maine to challenge the 340B Rebate Model Pilot Program.
AHA, MHA and Four Safety-Net Hospitals File Suit to Stop Unlawful 340B Changes Threatening Patient Care
Today, the American Hospital Association (AHA), the Maine Hospital Association (MHA) and four safety-net health systems from across the country filed a lawsuit in the United States District Court for the District of Maine to stop unlawful changes to a critical program that provides lower-cost drugs to hospitals and clinics that serve rural, poor and vulnerable communities.